Lenalidomid Glenmark (Lenalidomide)

Lenalidomide binds to cereblon, a component of the CRL4 E3 ubiquitin ligase complex, leading to the targeted degradation of transcription factors Ikaros and Aiolos. This triggers anti‑angiogenic effects, modulates cytokine release, enhances immune‑mediated tumor cell killing, and directly suppresses malignant cell growth.

The specific dose of Lenalidomid Glenmark is individualized and determined by the prescribing physician based on the patient’s diagnosis, disease stage, renal function, and prior therapies. Clinicians follow approved labeling and clinical guidelines to set the appropriate regimen.

Lenalidomid Glenmark is classified as Pregnancy Category X because it is teratogenic and can cause fetal harm. It should not be used by pregnant women, and effective contraception is required during treatment and for a defined period afterward. Use during breastfeeding is not recommended as the drug may pass into milk.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Both lenalidomide and thalidomide belong to the immunomodulatory imide drug (IMiD) class, but lenalidomide is more potent, has a shorter half‑life, and generally exhibits a more favorable safety profile, especially regarding peripheral neuropathy. Lenalidomide also demonstrates stronger anti‑angiogenic and immune‑stimulating effects, making it the preferred option for many approved indications.

Store Lenalidomid Glenmark at room temperature, below 25 °C, in the original blister pack or bottle. Keep the product away from moisture, direct sunlight, and excessive heat. Do not use if the packaging is damaged or if the tablets appear discolored.

Lenalidomid Glenmark is taken orally, usually once daily, with or without food, as directed by the prescriber. Swallow the tablet whole with a glass of water; do not crush, split, or chew unless specifically instructed. Adherence to the prescribed schedule is essential for optimal therapeutic effect.

The most serious risks include severe neutropenia or infection, thrombocytopenia leading to bleeding, venous thromboembolism, secondary primary malignancies, and serious hypersensitivity reactions such as Stevens‑Johnson syndrome. Patients should be monitored closely for signs of infection, clotting events, and unusual skin reactions.

Lenalidomid Glenmark is contraindicated in pregnant women, individuals with known hypersensitivity to lenalidomide or any component of the formulation, and patients with uncontrolled active infections. Caution is also advised for those with severe renal impairment, hepatic dysfunction, or a history of thromboembolic disease.